NASDAQ · COYA
Coya Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for COYA: Nov 11, 2026
Coya Therapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.35. The reported EPS for the same quarter last year was $-0.1.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.35 | $-0.33 | $-0.36 | 2 |
| Dec 2026 | $-0.39 | $-0.36 | $-0.42 | 2 |
| Mar 2027 | $-0.47 | $-0.44 | $-0.49 | 2 |
| Jun 2027 | $-0.48 | $-0.48 | $-0.48 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · BNK Invest · Fintel- Zacks · Jun 30, 9:40 AM EDTIs Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
- RTTNews · May 12, 8:04 AM EDTCoya Therapeutics: COYA 302 Receives FDA Fast Track Designation For Treatment Of ALS(RTTNews) – Coya Therapeutics (COYA) announced the FDA has granted Fast Track Designation for COYA 302, an investigational biologic combination therapy with a dual mechanism of action, for the treatment of amyotrophic lateral sclerosis. Coya is currently conducting the ALSTARS Tr
- Zacks · Feb 25, 12:00 PM ESTCoya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- BNK Invest · Jan 15, 12:34 PM ESTThursday Sector Laggards: Drugs, Biotechnology StocksIn trading on Thursday, drugs shares were relative laggards, down on the day by about 1.3%. Helping drag down the group were shares of Regencell Bioscience Holdings, down about 11.9% and shares of iBio down about 9.4% on the day. Also lagging the market Thursday are biotechnol
- Fintel · Dec 23, 7:04 PM ESTD. Boral Capital Maintains Coya Therapeutics (COYA) Buy RecommendationFintel reports that on December 23, 2025, D. Boral Capital maintained coverage of Coya Therapeutics (NasdaqCM:COYA) with a Buy recommendation. Analyst Price Forecast Suggests 204.13% Upside
- Fintel · Nov 14, 9:46 AM ESTChardan Capital Maintains Coya Therapeutics (COYA) Buy RecommendationFintel reports that on November 14, 2025, Chardan Capital maintained coverage of Coya Therapeutics (NasdaqCM:COYA) with a Buy recommendation. Analyst Price Forecast Suggests 177.49% Upside
- Fintel · Nov 13, 7:06 PM ESTBTIG Maintains Coya Therapeutics (COYA) Buy RecommendationFintel reports that on November 13, 2025, BTIG maintained coverage of Coya Therapeutics (NasdaqCM:COYA) with a Buy recommendation. Analyst Price Forecast Suggests 178.90% Upside
- Fintel · Sep 30, 8:02 AM EDTBTIG Reiterates Coya Therapeutics (COYA) Buy RecommendationFintel reports that on September 30, 2025, BTIG reiterated coverage of Coya Therapeutics (NasdaqCM:COYA) with a Buy recommendation. Analyst Price Forecast Suggests 199.93% Upside
- RTTNews · Sep 9, 1:11 AM EDTBiotech Stocks Surge After Hours: CAPR, TMDX Lead Gains Amid Trial Updates And Earnings Momentum(RTTNews) – Several biotech and medical technology stocks posted notable gains in after-hours trading on Monday, with momentum driven by a mix of earnings optimism, clinical trial progress, and speculative positioning. While some names rallied on fresh developments, like TransMed
- Zacks · Aug 27, 9:55 AM EDTCoya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?Is it a good or bad thing when a stock experiences a golden cross technical event?
- Zacks · Aug 12, 3:00 PM EDTCoya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue EstimatesCoya Therapeutics, Inc. (COYA) delivered earnings and revenue surprises of -63.64% and -96.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 7, 8:20 AM EDTRegenxbio (RGNX) Reports Q2 Loss, Lags Revenue EstimatesRegenxbio (RGNX) delivered earnings and revenue surprises of -22.12% and -21.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Coya Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.